Patents by Inventor Galina Kovalevskaya
Galina Kovalevskaya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150010926Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: July 15, 2014Publication date: January 8, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 8802381Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: March 18, 2013Date of Patent: August 12, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20140087393Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: March 18, 2013Publication date: March 27, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 8420339Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: April 13, 2012Date of Patent: April 16, 2013Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20130011858Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: April 13, 2012Publication date: January 10, 2013Inventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 8163508Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: July 12, 2011Date of Patent: April 24, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20110300557Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: July 12, 2011Publication date: December 8, 2011Inventors: John O' Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 7993858Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 7, 2010Date of Patent: August 9, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20110159526Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: September 7, 2010Publication date: June 30, 2011Inventors: John O' Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 7790403Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: October 22, 2007Date of Patent: September 7, 2010Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20080108089Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: October 22, 2007Publication date: May 8, 2008Inventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 7285391Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 1, 2004Date of Patent: October 23, 2007Assignee: The Trustees of Columbia Univeristy in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20070026466Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: September 27, 2006Publication date: February 1, 2007Inventors: John O'Connor, Galina Kovalevskaya, Steven Birken
-
Patent number: 7034124Abstract: This invention provides an antibody which specifically binds to hLH?cf without cross-reacting with hLH, hLH? or hCG?cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH?cf or hLH?cf-related molecule in a sample.Type: GrantFiled: September 23, 1999Date of Patent: April 25, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Steven Birken, John O'Connor, Galina Kovalevskaya
-
Patent number: 6927034Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: May 13, 1999Date of Patent: August 9, 2005Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20050042702Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: September 1, 2004Publication date: February 24, 2005Applicant: The Trustees of Columbia UniversityInventors: John Connor, Steven Birken, Galina Kovalevskaya
-
Publication number: 20020161198Abstract: This invention provides an antibody which specifically binds to hLH&bgr;cf without cross-reacting with hLH, hLH&bgr; or hCG&bgr;cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH&bgr;cf or hLH&bgr;cf-related molecule in a sample.Type: ApplicationFiled: September 23, 1999Publication date: October 31, 2002Inventors: ROBERT E. CANFIELD, STEVEN BIRKEN, JOHN O'CONNOR, GALINA KOVALEVSKAYA
-
Patent number: 5976876Abstract: This invention provides an antibody which specifically binds to hLH.beta.cf without cross-reacting with hLH, hLH.beta. or hCG.beta.cf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No.12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLH.beta.cf or hLH.beta.cf-related molecule in a sample.Type: GrantFiled: December 11, 1996Date of Patent: November 2, 1999Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Steven Birken, John O'Connor, Galina Kovalevskaya